The Chemopreventive Agent Development Research Group (CADRG) promotes and supports research on cancer preventive agent development, from preclinical studies to phase I clinical trials. The group’s projects aim to intercept the carcinogenic process by identifying and developing preventative agents with the potential to block, reverse, or delay the early stages of cancer. In addition, the group supports research on clinically translatable biomarkers that can be used to monitor tumor initiation and progression or assess efficacy of preventive interventions.
Read more About the Chemopreventive Agent Development Research Group.
News and Events
Biomedical Engineering Society (BMES) 2024 Annual Meeting
Date Posted: October 21, 2024
DCP Participation at Biomedical Engineering Society (BMES) Annual Meeting - October 24, 2024
Date Posted: October 15, 2024
Targeting Prevention to Reduce the High Human Toll of Rare Cancers
Date Posted: October 1, 2024
Microbial Host Defense and Effect on Cancer Initiation and Progression
Date Posted: July 11, 2024